CytomX Therapeutics Inc. ( (CTMX) ) has released its Q3 earnings. Here is a breakdown of the information CytomX Therapeutics Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
CytomX Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel, conditionally activated biologics for cancer treatment, utilizing its proprietary PROBODY® therapeutic platform. In its third-quarter 2025 earnings report, CytomX highlighted significant progress in its clinical pipeline, particularly with its lead programs CX-2051 and CX-801. The company is on track to provide a Phase 1 data update for CX-2051 in early 2026, with plans to advance this candidate towards a registrational study for colorectal cancer (CRC). Additionally, CytomX reported promising biomarker data for CX-801, supporting its ongoing combination study with KEYTRUDA® in melanoma.
Key financial metrics revealed a decrease in total revenue to $6 million for the quarter, primarily due to the completion of obligations under a collaboration with Bristol Myers Squibb and reduced activities with Moderna. Operating expenses also decreased, with research and development costs dropping due to program de-prioritization and restructuring. The company ended the quarter with $143.6 million in cash and investments, providing a cash runway into mid-2027.
Strategically, CytomX is focusing on advancing its lead candidates, exploring additional indications for CX-2051, and continuing its collaborations with major pharmaceutical companies like Amgen and Moderna. The recent appointment of Rachael Lester as Senior Vice President, Chief Business Officer, is expected to bolster its strategic initiatives.
Looking ahead, CytomX remains committed to advancing its clinical programs and exploring new therapeutic opportunities within its pipeline. The management’s focus on strategic investments and collaborations positions the company to potentially expand its impact in the oncology sector, with upcoming data readouts and trial initiations in 2026 expected to be pivotal.